Are reverse payments and pay-for-delay settlements business as usual or an anticompetitive practice?

Nat Biotechnol. 2016 Jul 12;34(7):716-9. doi: 10.1038/nbt.3627.
No abstract available

MeSH terms

  • Drug Industry / economics*
  • Drug Industry / legislation & jurisprudence*
  • Economic Competition / economics*
  • Economic Competition / legislation & jurisprudence*
  • Legislation, Drug / economics*
  • Patents as Topic / legislation & jurisprudence*
  • United States
  • United States Federal Trade Commission / legislation & jurisprudence